Evidence map›Paper›PMID 30820596›Full record

ArticleArchivum immunologiae et therapiae experimentalis2019

The Expression of the SLIT-ROBO Family in Adult Patients with Acute Myeloid Leukemia.

Aleksandra Gołos, Dorota Jesionek-Kupnicka, Lidia Gil, Marcin Braun, Mieczyslaw Komarnicki, Tadeusz Robak, Agnieszka Wierzbowska

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archivum immunologiae et therapiae experimentalis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Science advances · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Aleksandra GołosDepartment of Hematology, Medical University, Lodz, Poland. alexandra_golos@tlen.pl.ORCID http://orcid.org/0000-0002-7780-3587
Dorota Jesionek-KupnickaDepartment of Pathology, Medical University, Lodz, Poland.
Lidia GilDepartment of Hematology, University of Medical Sciences, Poznan, Poland.
Marcin BraunDepartment of Pathology, Medical University, Lodz, Poland.
Mieczyslaw KomarnickiDepartment of Hematology, University of Medical Sciences, Poznan, Poland.
Tadeusz RobakDepartment of Hematology, Medical University, Lodz, Poland.
Agnieszka WierzbowskaDepartment of Hematology, Medical University, Lodz, Poland.
Medical University of Lodz · PLPoznan University of Medical Sciences · PLInstitute for Transfusion Medicine · USMedical University of Warsaw · PL

Funding

Uniwersytet Medyczny w Lodzi 502-03/1-093-01/502-14-077Uniwersytet Medyczny w Lodzi 503/1-093-01/503-11-001
6 · The paper itself

Abstract

introductionSLIT-ROBO is a ligand-receptor family of neuronal guidance cues that has been involved in pathological and physiological angiogenesis. SLIT-ROBO expression is altered in many tumours. However, no data exist about the role of the whole family in acute myelogenous myeloid leukemia (AML). PURPOSE: Herein, we assessed the expression of all SLIT-ROBO family in bone marrow (BM) biopsy of AML patients and control group on both protein and RNA levels.

methodsThe paraffin-embedded tissue blocks were subjected to immunohistochemistry for SLIT1, SLIT2, SLIT3, ROBO1, ROBO2, ROBO3, and ROBO4. Microvessel density (MVD) was evaluated by CD34 immunohistochemistry. An in silico analysis using The Cancer Genome Atlas data repository was conducted for assessment of RNA level.

resultsAcute myeloid leukemia patients were generally high expressers of ROBO1 and ROBO2 compared to the controls (p < 0.0001, p < 0.001, respectively). In contrast, low expression of SLIT1, SLIT2, and SLIT3 ligands has been noted more commonly in AML than in control BM samples (p < 0.0001, p = 0.003, and p = 0.001, respectively). ROBO4 expression correlated with MVD. The in silico analysis showed a poor prognostic value of high ROBO3 and low SLIT2 RNA levels (p = 0.0003 and p = 0.0008, respectively), as well as high ROBO3 and ROBO4 RNA levels in cytogenetic poor risk groups of patients (p = 0.0029 and p = 0.0003, respectively).

conclusionsThese data indicate that SLIT-ROBO family members play a role in the biology of AML. Low expression of SLIT in BM of AML patients may suggest its expression alterations in AML. Increased expression of ROBO1 and ROBO2 in AML patients suggests their participation in AML pathogenesis.

Indexed as

AdolescentAdultAgedAged, 80 and overAxon GuidanceFemaleGene Expression Regulation, NeoplasticHumansIntercellular Signaling Peptides and ProteinsLeukemia, Myeloid, AcuteMaleMembrane ProteinsMiddle AgedNeovascularization, PathologicNerve Tissue ProteinsReceptors, Cell SurfaceIntercellular Signaling Peptides and ProteinsMembrane ProteinsNerve Tissue ProteinsReceptors, Cell SurfaceReceptors, ImmunologicROBO2 protein, humanROBO3 protein, humanROBO4 protein, humanRoundabout ProteinsSLIT1 protein, humanSLIT3 protein, humanSlit Homolog 2 ProteinAcute myeloid leukemiaAngiogenesisNerve tissue proteinsROBO proteinSLIT protein

Identifiers

PMID30820596
PMCPMC6420492
OpenAlexW2918589399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.